Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Aim(s): The objective of this study was to evaluate efficacy and tolerance of Dacarbazine- or Temozolomide-based chemotherapy in metastatic digestive NEC in post first-line chemotherapy.
Materials and methods: This study included patients with a metastatic NEC of digestive or unknown primary. All of them received platinum-etoposide in first-line chemotherapy. The primary endpoint was progression free survival (PFS). Secondary endpoints were: clinical/biological (ALP decrease >30%)/morphological (RECIST) response, toxicity, and overall survival (OS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
To read results and conclusion, please login ...
Further abstracts you may be interested in